Title:
ＦＬＴ３を標的にするキメラ抗原受容体
Document Type and Number:
Japanese Patent JP7317718
Kind Code:
B2
Abstract:
Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).
Inventors:
Barbra Johnson Sus
Daniel Elizabeth Deadling
Caesar Adolfo Summer
Ick Andy Yeung
Mustafa Mark Khamseh
Daniel Elizabeth Deadling
Caesar Adolfo Summer
Ick Andy Yeung
Mustafa Mark Khamseh
Application Number:
JP2019566197A
Publication Date:
July 31, 2023
Filing Date:
May 31, 2018
Export Citation:
Assignee:
Pfizer Inc.
International Classes:
C12N15/62; A61K31/7088; A61K35/17; A61K38/16; A61K39/395; A61K48/00; A61P35/00; A61P35/02; C07K14/705; C07K16/40; C07K19/00; C12N5/10; C12N15/13; C12N15/63; C12Q1/02; G01N33/53
Domestic Patent References:
| JP2017513478A |
Foreign References:
| WO2017053889A2 | ||||
| US20160297884 |
Attorney, Agent or Firm:
Norito Yamao
Norifumi Tomita
Fumio Inai
Norifumi Tomita
Fumio Inai
Previous Patent: Systems and methods that enable memory-bound continuous learning in artificial intelligence and deep...
Next Patent: ONE-TOUCH CLIP
Next Patent: ONE-TOUCH CLIP